This study contributes to the work of Dr Frank Prior who is developing a tool to be used in the treatment of shock.
It is known that shock creates a set of internal conditions that affect vasculature and that these conditions can vary over time and are dependent on the type of shock. This tool reveals the condition of the vasculature and therefore informs which fluid and drugs are best advised for that patient at that time. The tool is based on patient pore size, Mean Osmotic Pressure (MOP) and Mean Arterial Pressure (MAP). As the ability to measure MOP is expensive and rare in the UK, this study is an unique opportunity to investigate if calculating MOP from biochemistry results is accurate by comparing measured and calculated MOP. This is an observational study recruiting 20 healthy volunteers from the orthopaedic pre-assessment clinic. We are very excited about this study as the tool would given clinicians the ability to treat patients with regard to their individual pathophysiology and is therefore in line with a precision medicine based approach.
This study will commence on the 30th May 2016.
1. Ambulatory Device, Rocket Pleural vent insertion
2. Standard Treatment, Aspiration +/- chest drain
Primary Outcome Measures
To assess whether use of an ambulatory device (Rocket Pleural Vent) and treatment strategy reduces hospital stay. Total length of stay in hospital up to 30 days post randomisation. Up to 30 days post randomisation.
RAMPP trial - Randomised Controlled Trial: Pleural vent (rocket) V standard care in Primary Spontaneous Pnuemothorax
Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.
Identification of Novel Psychoactive Substances (IONA)